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OBJECTIVE—Increased glomerular ﬁltration rate (GFR), also called hyperﬁltration, is a pro-
posed mechanism for renal injury in diabetes. The causes of hyperﬁltration in individuals with-
out diabetes are largely unknown, including thep o s s i b l er o l eo fb o r d e r l i n eh y p e r g l y c e m i a .
Weassessedwhetherimpairedfastingglucose(IFG;5.6–6.9mmol/L),elevatedHbA1c,orhyper-
insulinemia are associated with hyperﬁltration in the general middle-aged population.
RESEARCH DESIGN AND METHODS—A total of 1,560 individuals, aged 50–62 years
withoutdiabetes,wereincludedintheRenalIohexolClearanceSurveyinTromsø6(RENIS-T6).
GFR was measured as single-sample plasma iohexol clearance. Hyperﬁltration was deﬁned as
GFR.90thpercentile,adjustedfor sex,age,weight,height,anduseofrenin-angiotensinsystem
inhibitors.
RESULTS—Participants with IFG had a multivariable-adjusted odds ratio of 1.56 (95% CI
1.07–2.25) for hyperﬁltration compared with individuals with normal fasting glucose. Odds
ratios (95% CI) of hyperﬁltration calculated for a 1-unit increasein fasting plasma glucose (FPG)
and HbA1c, after multivariable-adjustment, were 1.97 (1.36–2.85) and 2.23 (1.30–3.86). There
was no association between fasting insulin levels and hyperﬁltration. A nonlinear association
between FPG and GFR was observed (df = 3, P , 0.0001). GFR increased with higher glucose
levels, with a steeper slope beginning at FPG $5.4 mmol/L.
CONCLUSIONS—Borderline hyperglycemia was associated with hyperﬁltration, whereas
hyperinsulinemia was not. Longitudinal studies are needed to investigate whether the hyper-
ﬁltration associated with IFG is a risk factor for renal injury in the general population.
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C
hronic kidney disease (CKD) is rec-
ognized as a global health problem.
The prevalence of CKD is estimated
to exceed 10% in Western societies and
in many Asian countries (1). Concur-
rently, the incidence of obesity and pre-
diabetes, deﬁn e da si m p a i r e df a s t i n g
glucose (IFG) or impaired glucose toler-
ance, has reached epidemic proportions
worldwide (2). Growing evidence links
prediabetes and insulin resistance to
microalbuminuriaandCKD,butthepath-
ophysiologic mechanisms for renal injury
have not been elucidated (3,4). However,
studies in animals and humans indicate
that an abnormally elevated glomerular
ﬁltration rate (GFR), or hyperﬁltration,
mayincreasethesusceptibilitytorenalin-
jury in obesity and in diabetes (5,6).
At the single-nephron level, hyper-
ﬁltration is hypothesized to be an early
link in the chain of events that lead from
intraglomerular hypertension to albu-
minuria and, subsequently, to reduced
GFR (7). This paradigm has received at-
tention in experimental research, but is
difﬁcult to study at the population level
because obtaining accurate measure-
ments of GFR is complicated and time-
consuming. GFR estimated from creatinine
or cystatin C levels is imprecise in the
normal or upper range of GFR and is
biased in individuals with atypical body
composition or creatinine production (8).
Accordingly, although hyperglycemia is
known to mediate hyperﬁltration in dia-
betes, the causes of hyperﬁltration in the
general population are largely unknown;
particularly, whether prediabetes or insu-
lin resistance is associated with hyperﬁl-
tration is unknown.
The current study investigated whether
IFG, elevated HbA1c, hyperinsulinemia,
or insulin resistance are associated with
hyperﬁltration in a general middle-aged
population. To avoid the problems of
estimating GFR from creatinine or cystatin
C values, we measured GFR as iohexol
clearance, which is recognized as an accu-
rate method (9).
RESEARCH DESIGN AND
METHODS—The Renal Iohexol Clear-
ance Survey in Tromsø 6 (RENIS-T6) is
a part of the population-based sixth
Tromsø study (Tromsø 6) in the munici-
pality of Tromsø, Northern Norway.
Tromsø 6 was conducted in 2007 through
2008 and included an age-stratiﬁed repre-
sentative sample of 12,984 inhabitants of
Tromsø. Among the 5,464 invited per-
sons in the group aged 50 to 62 years,
3,564 (65%) met and completed the
main part of Tromsø 6, which included
a self-administered questionnaire on
health status, a physical examination,
and collection of three separate morning
spot urine samples. From this group, the
2,825 subjects without previous myocar-
dial infarction, angina pectoris, stroke, di-
abetes, or renal disease were invited to
participate in RENIS-T6 (Supplementary
Fig. 1).
The age-group of 50 to 62 years
was chosen to study a relatively healthy
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ORIGINAL ARTICLEpopulation, but with a sufﬁcient risk of
CKDandcardiovasculardiseaseforalater
end point study. A detailed description of
RENIS-T6 has been published elsewhere
(10).Brieﬂy,2,107(75%)respondedpos-
itively and 72 were excluded. A total of
1,632 subjects were included according
to a predetermined target size. The char-
acteristics of the RENIS-T6 cohort were
comparable with the 2,825 eligible re-
cruits, as previously reported (10). For
the present analyses, subjects with fasting
plasma glucose (FPG) $7.0 mmol/L or
HbA1c $6.5% were considered to have
diabetes and were excluded. We also ex-
cluded subjects with an iohexol clearance
,60 mL/min/1.73 m
2 according to the
deﬁnition of CKD.
Study participants met in the morn-
ing after an overnight fast, including
abstinence from tobacco. Blood pressure
(BP) was measured three times with an
automatic device (model UA-799, A&D
Medical, San Jose, CA), and the last two
readings were averaged. A Teﬂoncatheter
wasplacedinanantecubitalveinandfast-
ing plasma samples were drawn for bio-
chemical analyses. Iohexol (5 mL) was
injected, and the syringe was weighed be-
fore and after injection. The venous cath-
eter was ﬂushed with 30 mL of isotonic
saline. The iohexol blood sample was
drawn from the same catheter and the
iohexol concentration was measured by
high-performance liquid chromatography.
GFR was calculated as described by
Jacobsson (11). Details about the iohexol
clearance measurements were published
previously (10). Plasma creatinine levels
were analyzed by the enzymatic method
that was standardized against isotope
dilution mass spectroscopy. Cystatin C
was measured by particle-enhanced tur-
bidimetric immunoassay (Gentian, Moss,
Norway).WeestimatedGFR(eGFR)from
creatinine or cystatin C by using the re-
calibrated four-variable Modiﬁcation of
Diet in Renal Disease (MDRD) equation,
the Chronic Kidney Disease Epidemiol-
ogy Collaboration (CKD-EPI) equation,
and Rule’s equation of 2006 (12,13).
Values for FPG, triglycerides, and choles-
terol were measured on the Modular
model P800 (Roche Diagnostics Corp.,
Indianapolis, IN). IFG was deﬁned ac-
cording to the American Diabetes Associ-
ation criteria of 5.6–6.9 mmol/L for FPG.
The insulin samples were measured
with an ELISA kit (DRG Instruments, Mar-
burg, Germany). The intraassay and inter-
assaycoefﬁcientsofvariationwere4.7and
6.3%.Insulinresistance(IR)wasexpressed
by homeostasismodel assessment(HOMA)-
IR: [FPG (mmol/L) 3 fasting insulin
(mU/L)]/22.5.
HbA1c, urinary albumin excretion
(UAE), and urinary creatinine were mea-
s u r e di nt h em a i np a r to fT r o m s ø6 .
HbA1c w a sm e a s u r e dw i t hal i q u i dc h r o -
matographic method. UAE and urinary
creatinine were measured with commer-
cial kits, as described in a previous study
(14). The albumin/creatinine ratio (ACR)
was calculated for each urine specimen,
and the mean ACR value was used in the
analyses (14).
We estimated age- and sex-adjusted
means or median values across two
groups: those with normal FPG and those
with IFG. Differences across groups were
tested bylinear regressionfor mean values,
quantile regression for median values, and
multiple logistic regression for dichoto-
mous variables. The associations between
GFR expressed in mL/min/1.73 m
2 and
FPG, HbA1c, fasting insulin, and HOMA-
IR were assessed by multiple linear regres-
sion analysis, adjusting for the following
known or possible determinants of GFR:
age, sex, height, weight, current smoking,
diastolic BP, and current use of ACE
inhibitors or angiotensin receptor block-
ers (ARB). The same analyses were re-
peated for the absolute GFR expressed in
mL/min.
To investigate a possible nonlinear
association between FPG and GFR, we
used local regression smoothing in a
generalized additive model, adjusting for
the same variables as in the linear re-
gression analyses. Renal hyperﬁltration
was deﬁn e da sa na b s o l u t eG F R.90th
percentile after adjusting for sex, age,
weight, height, and the use of ACE inhib-
itors or ARB. This was done by selecting
all subjects.90th percentilein the distri-
bution of residuals from a multiple linear
regressionanalysiswhereweusedthelog-
arithm of absolute GFR as a dependent
variable and sex, use of ACE inhibitors
or ARB, and the logarithm of age, weight,
and height as independent variables.
Multiple logistic regression analyses
were performed to determine the odds
ratios of hyperﬁltration associated with
the same independent variables, and ad-
justedforage,sex,height,weight,current
smoking, diastolic BP, and use of ACE
inhibitors or ARB. The same linear and
logistic regression analyses were repeated
with adjustment for BMI instead of for
height and weight. We tested for inter-
actions between the independent vari-
ablesandsex,age,andBMIinallanalyses.
Stata 11 software (Stata Corp., College
Station, TX) was used for the statistical
analysis. Generalized additive models
were analyzed using PROC GAM in SAS
9.2 software (SAS Institute, Cary, NC).
StatisticalsigniﬁcancewassetatP,0.05.
The study was approved by the regional
ethics committee of Northern Norway.
All subjects provided informed written
consent.
RESULTS—The study excluded 33 in-
dividuals with diabetes according to their
FPG or HbA1c results, 34 with measured
GFR ,60 mL/min/1.73 m
2,a n d5w i t ha
failure in the iohexol measurement (Sup-
plementary Fig. A1).
IFG was present in 311 men (40%)
and 141 women (18%). Table 1 reports
thecharacteristicsofthestudypopulation
divided by glucose status, adjusted for
age and sex. Individuals with IFG had
higher BMI, insulin levels, and BP, but
not higher ACR compared with those
with normal FPG. Measured GFR, but not
creatinine- or cystatin C–based eGFR, was
higher inindividualswith IFG (P =0 . 0 0 2 ) .
Multiple linear regression analyses
with measured GFR as a dependent vari-
able are reported in Table 2. FPG, HbA1c,
fasting insulin, and HOMA-IR were posi-
tively associated with GFR in separate
models when adjustedfor age, sex, weight,
height, diastolic BP, current smoking, and
use of ACE inhibitors or ARB. Because of
collinearity, HOMA-IR and insulin were
analyzed in separate models. Regression
diagnostics did not indicate problems
with collinearity between FPG and insulin
or HOMA-IR. The effect estimates of in-
sulin and HOMA-IR were no longer sig-
niﬁcant in models including FPG. There
were no signiﬁcant interactions among
age, sex, or BMI and the predictor vari-
ables listed in Table 2. The pattern of sta-
tistically signiﬁcant estimates was similar
when we used the logarithm of absolute
GFR as the dependent variable and the
same independent variables but with log-
transformed age, weight, and height (not
shown). A nonlinear association between
FPG and GFR was observed by using local
regression smoothing in a generalized
additive model, after multivariable adjust-
ment (df = 3, P , 0.0001; Fig. 1). GFR
increased with higher glucose levels,
with a steeper slope beginning at FPG
$5.4 mmol/L.
T h e7 9w o m e na n d7 7m e nw i t h
hyperﬁltration had mean GFRs of 110.1
(range 98.7–138.6) and 118.2 (107.5–
137.3) mL/min/1.73 m
2,c o m p a r e dw i t h
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2 for
women and men with normal ﬁltration.
Multivariable-adjusted odds ratios for
hyperﬁltration in relation to metabolic
factors are reported in Table 3. Higher
levels of FPG, HbA1c,a n dH O M A - I R ,
andhavingIFG,were signiﬁcantlyassoci-
ated with an increased odds ratio of
hyperﬁltration. Fasting insulin level was
not associated with hyperﬁltration. The
effect of FPG and IFG remained strong
and signiﬁcant after additional adjust-
ment for HDL cholesterol, triglycerides,
insulin, ACR, and BMI (not shown).
HOMA-IR, however, was not associated
with hyperﬁltration after adjusting for
FPG (model 8). All the logistic regression
models were repeated with a stricter def-
inition of hyperﬁltration by deﬁning only
those with adjusted absolute GFR .95th
percentile as having hyperﬁltration. These
analyses yielded similar ﬁndings. Some
degree of hemolysis was found in 180 se-
rum samples (11%), and this signiﬁcantly
inﬂuenced the mean insulin levels but not
the mean glucose levels. However, both
the linear and logistic regression estimates
remained essentially the same after ex-
cluding individuals with hemolysis in se-
rum samples.
CONCLUSIONS—In this middle-
aged population without diabetes, we
found that IFG was associated with hy-
perﬁltration independent of age, sex,
BMI, BP, smoking status, and insulin
levels.Asimilarassociationwasfoundbe-
tween HbA1c and hyperﬁltration, which
indicates not only an acute effect but
also an effect of chronically elevated glu-
cose levels on GFR. Furthermore, we
observed a nonlinear association between
FPG and GFR, with steepening of the re-
gression curve at FPG $5.4 mmol/L.
Experimental studies in healthy sub-
jects have shown increased GFR was
induced by acute glucose infusion, but
plasma glucose in these experiments was
increasedto.7.0mmol/L(15).Indogs,a
continuous glucose infusion for 6 days,
producing a modest rise in serum glucose
from 6.5 to 7.1 mmol/L, increased GFR
signiﬁcantly (16). To our knowledge, no
previous human studies have found that
glucose levels in the nondiabetic range
signiﬁcantly and independently inﬂuence
GFR. A few studies found that FPG in the
nondiabetic range was associated with in-
creased GFR, but these studies did not
adjust GFR for sex, body size, or body
weight (17). FPG was not associated
with hyperﬁltration in two previous hy-
perﬁltration studies in nondiabetic indi-
viduals (18,19). However, these studies
used creatinine clearance or creatinine-
based eGFR, which are limited by low
precisionandbias,especiallyinthe upper
GFR range (8).
The estimating formulas are also
inﬂuenced by non-GFR factors such as
Table 1—General characteristics of the study population grouped by glycemic category*
Fasting glucose
Normal† Impaired‡
Variable n = 1,108 n =4 5 2 P
Male sex 42 69 ,0.001
Age (years) 57.8 6 3.7 58.5 6 3.9 0.001
BMI (kg/m
2) 26.7 6 3.8 28.4 6 3.9 ,0.001
Overweight 48 48 0.86
Obese 18 32 ,0.001
Current daily smoking 23 18 0.02
Systolic BP (mmHg) 128.6 6 16.6 131.4 6 16.9 0.003
Diastolic BP (mmHg) 83.0 6 9.4 84.5 6 9.6 0.005
Triglyceride level (mmol/L) 0.9 (0.7–1.4) 1.1 (0.8–1.6) ,0.001
HDL cholesterol level (mmol/L) 1.55 6 0.40 1.50 6 0.40 0.03
Fasting glucose (mmol/L) 5.1 6 0.3 5.9 6 0.3
HbA1c level (% unit) 5.5 6 0.3 5.7 6 0.3 ,0.001
Fasting insulin level (mU/mL) 7.7 (5.4–10.6) 10.8 (7.8–14.7) ,0.001
HOMA-IR (index) 1.7 (1.2–2.4) 2.9 (2.1–3.9) ,0.001
ACR (mg/mmol) 0.33 (0.19–0.59) 0.31 (0.18–0.58) 0.18
Measured GFR§ 100.7 6 15.0 106.1 6 15.2 ,0.001
Adjusted for BSA 91.8 6 12.4 94.0 6 12.6 0.002
eGFR
MDRD|| 94.4 6 16.2 94.2 6 16.4 0.8
CKD-EPI¶ 95.2 6 8.8 95.0 6 8.9 0.69
Cystatin C# 92.6 6 16.4 92.7 6 16.7 0.91
Values are expressed as means 6 SD, percentages, or medians (interquartile range). BSA, body surface area.
*Values are adjusted by age and sex. †Normal fasting glucose: ,5.6 mmol/L (,100 mg/dL). ‡IFG: 5.6–6.9
mmol/L (100–125 mg/dL). §GFR (mL/min/1.73 m2) measured by single-sample iohexol clearance. ||GFR
(mL/min/1.73 m
2) estimated by the MDRD equation (12). #GFR (mL/min/1.73 m
2) estimated by Rule’s
cystatin C–based equation of 2006 (13). ¶GFR (mL/min/1.73 m
2) estimated by the CKD-EPI equation (12).
Table 2—Multiple linear regression analyses with measured GFR as the
dependent variable
Independent variable b Coefﬁcient 95% CI P
Model 1
BMI, per unit 0.04 20.12 to 0.21 0.64
Model 2
Fasting glucose, per mmol/L (18 mg/dL) 3.67 2.29–5.06 ,0.001
Model 3
HbA1c,p e r%u n i t 2 . 3 8 0 . 4 6 –4.31 0.015
Model 4
Fasting insulin, per mU/mL 0.16 0.03–0.29 0.015
Model 5
HOMA-IR, per unit 0.80 0.31–1.29 0.001
Model 6
Fasting glucose, per mmol/L (18 mg/dL) 3.46 2.02–4.89 ,0.001
Fasting insulin, per mU/mL 0.08 20.05 to 0.21 0.230
Model 7
Fasting glucose, per mmol/L (18 mg/dL) 3.28 1.78–4.78 ,0.001
HOMA-IR, per unit 0.36 20.16 to 0.89 0.177
All models except model 1 were adjusted for age, sex, weight, height, diastolic BP, current smoking, and the
use of ACE inhibitors or ARB. Model 1wasadjusted for thesame variablesexceptfor weightand height.GFR
was measured by iohexol clearance and expressed as mL/min/1.73 m
2.
1548 DIABETES CARE, VOLUME 34, JULY 2011 care.diabetesjournals.org
FG associated with renal hyperﬁltrationbodycompositionandglycemicstatus(20).
In the current study, we found a signiﬁ-
cantly higher measured GFR but not higher
creatinine- or cystatin C–based eGFR in
persons with IFG. This demonstrates the
difﬁculty of studying hyperﬁltration with
eGFR. Cystatin C was recently proposed
as a new and better marker of renal func-
tion in the normal GFR range. However,
cystatin C is also inﬂuenced by non-GFR
factors. We recently showed that cystatin
C–based eGFR did not perform better
than creatinine-based eGFR when vali-
dated against iohexol clearance in the
general population (10). We are aware of
only one previous study that measured
GFR to assess the association between
IFG and hyperﬁltration. In a study that
included 363 participants of African de-
scent with a positive family history of
hypertension, individuals with IFG had
an increased risk of hyperﬁltration, al-
though not statistically signiﬁcant (21).
Hyperﬁltration in this study was deﬁned
as GFR .140 mL/min/1.73 m
2, without
adjusting for age and sex.
In the current study, fasting insulin
levelsandHOMA-IRwereassociatedwith
increased GFR in the linear regression
analysis, but not after adjusting for FPG.
Furthermore, insulin levels were not as-
sociated with hyperﬁltration. Previous
population studies of insulin levels and
GFR are scarce, none included an exact
method to measure GFR, and the results
are divergent (22). Nevertheless, hyper-
insulinemia and insulin resistance are
both proposed as mediators of hyperﬁl-
tration and subsequent renal injury in
obesity (22). Our results are inconsistent
with the hypothesis that hyperinsuline-
mia causes hyperﬁltration in the general
population where overweight and obesity
is prevalent. Thus as previously sugges-
ted, mechanisms other than hyperﬁltra-
tion, such as inﬂammatory cytokines or
lipotoxicity, may link insulin resistance
to kidney damage (5).
Unlike most previous hyperﬁltration
studies (18,19,21), we adjusted for age,
sex, height, and body weight when deﬁn-
ing hyperﬁltration. There is no consensus
on how to deﬁne hyperﬁltration. The clin-
ical relevance of hyperﬁltration is based on
a proposed pathologic effect of increased
single-nephron GFR, which cannot be
measured in humans. Instead, whole-
kidney hyperﬁltration, with a threshold
arbitrarily set in different studies from
125to140mL/min/1.73m
2,wasassumed
to reﬂect hyperﬁltration at the glomerular
level (6). However, because the number of
nephrons varies signiﬁcantly between in-
dividuals, whole-kidney GFR will reﬂect
variation in nephron number as well as
in single-nephron GFR. Moreover, GFR
and nephron number both decrease with
age and are lower in women than in men
(23). A noncorrected threshold for hyper-
ﬁltration would mask hyperﬁltration at
older ages and in women. Because body
weightcouldconfoundtheassociationbe-
tween IR or prediabetes and hyperﬁltra-
tion, we chose to adjust GFR not only
for age, sex, and height but also for body
weight,inthedeﬁnitionofhyperﬁltration.
Figure 1—A nonlinear effect of fasting glucose on measured GFR, calculated by local regression
smoothing in a generalized additive model (df = 3, P, 0.0001), and adjusted for age, sex, height,
weight, current smoking, diastolic BP, and the use of ACE inhibitors or ARB.
Table 3—Multiple logistic regression analyses of odds ratio for hyperﬁltration
Independent variable Odds ratio* (95% CI) P
Model 1
BMI, per unit 1.02 (0.98–1.06) 0.38
Model 2
Fasting glucose, per mmol/L (18 mg/dL) 1.97 (1.36–2.85) ,0.001
Model 3
HbA1c,p e r%u n i t 2 . 2 3( 1 . 3 0 –3.86) 0.004
Model 4
IFG†,y e s / n o 1 . 5 6( 1 . 0 7 –2.25) 0.019
Model 5
Insulin, per mU/mL 1.03 (1.00–1.06) 0.08
Model 6
IFG†,y e s / n o 1 . 4 8( 1 . 0 1 –2.25) 0.04
Insulin, per mU/mL 1.02 (0.99–1.05) 0.20
Model 7
HOMA-IR, per unit 1.14 (1.01–1.28) 0.033
Model 8
Fasting glucose, per mmol/L (18 mg/dL) 1.86 (1.25–2.76) 0.002
HOMA-IR, per unit 1.06 (0.93–1.20) 0.41
*Allmodelsexcept model 1were adjustedfor age, sex, weight,height,diastolicBP, current smoking, and the
use of ACE inhibitors or ARB. Model 1 was adjusted for the same variables except weight and height. Models
6 and 8 were also adjusted for the other variable in the same model. †IFG: 5.6–6.9 mmol/L (100–125 mg/dL).
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tion in hyperglycemia is not fully un-
derstood, but studies in diabetic animals
indicate a key role of increased sodium
reabsorption through sodium-glucose
cotransport in the proximal renal tubules
(24). Raised proximal sodium reabsorp-
tion is also found in individuals with IFG
compared with subjects with normal FPG
(21). Furthermore, other factors associated
with hyperglycemia, such as nitric oxide,
vascular inﬂammation, oxidative stress, or
activation of the renin-angiotensin sys-
tem, could alter renal vascular tone, and
consequently, increase GFR (24).
There is solid evidence that increased
glomerular pressure causes kidney dam-
age, but there is less evidence that glo-
merular hyperﬁltration per se is harmful
(5). For example, the long-term risk of
proteinuria and end-stage renal disease
after kidney donation, a state that implies
hyperﬁltration in the remaining kidney,
is similar to that in the general popula-
tion. However, transplant donors are
carefully selected individuals without
other CKD risk factors; therefore, their
risk of renal failure should be low.
In contrast, a high risk of developing
proteinuria was found after unilateral
nephrectomy for reasons other than kid-
ney donation, particularly in overweight
individuals (25). We are aware of only
one prospective study of hyperﬁltration
in nondiabetic individuals. In a study of
subjects with stage 1 hypertension, the
risk of developing microalbuminuria
was increased in those with hyperﬁltra-
tion at baseline (19). These ﬁndings are
consistentwith the“multi-hithypothesis”
of CKD, where hyperﬁltration in concert
with other CKD risk factors causes kidney
injury.Indiabetes,somebutnotallstudies
showed an association between hyperﬁl-
tration and the subsequent development
of nephropathy (6).
IFG is present in approximately 30%
of the adult U.S. population, and CKD
was recently found in 17% of individuals
with IFG compared with 12% of those
with normal FPG (2,4). Moreover, an in-
crease in FPG within the normal range, or
increased HbA1c, were both associated
with progression of UAE in the general
nondiabetic population (3,14). In the
current study, which included a relatively
healthy population, IFG was not associ-
ated with ACR. Longitudinal studies with
an exact method of measuring GFR
are needed to explore the temporal rela-
tionship between IFG, hyperﬁltration,
UAE, and CKD.
Some limitations in our study should
be noted. The cross-sectional design limits
inferences on causality. The study popula-
tion consisted of middle-aged Caucasians
only, thus the results cannot automatically
be generalized to other age-groups or pop-
ulations. In addition, IR was not measured
with the gold standard euglycemic clamp
method. However, the HOMA-IR corre-
lates well with values obtained with the
euglycemic clamp technique and remains
the preferred method in epidemiologic
studies.
The strength of this study includes
the use of an exact method to measure
GFR in a large sample of the general
population. We conclude that IFG is asso-
ciated with an increased risk of hyper-
ﬁltration in the middle-aged nondiabetic
population. Hyperﬁltration caused by IFG
may be one of several mechanisms for
renal injury in the general population.
Longitudinal studies are needed to explore
whether hyperﬁltration increases the risk
of CKD in nondiabetic individuals.
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